Specificity is a prerequisite for systemic gene therapy of hepatocarcinoma. In vitro, the tumor-specific viral death effector Apoptin selectively induces apoptosis in malignant hepatic cells. Intratumoral treatment of xenografted subcutaneous hepatomas with Apoptin results in tumor regression. Here, we report a systemic delivery vehicle containing the Apoptin gene linked to asialoglycoprotein (Asor), which targets asialoglycoprotein receptor (ASGPR) present only on the surface of hepatocytes. In vitro, the protein-DNA complex Asor-Apoptin induced apoptosis in HepG2 hepatocarcinoma cells but not in normal L-02 hepatocytes. Non-hepatocyte-derived tumorigenic human A549 cells lacking the membrane ASGPR were not affected by Asor-Apoptin. In vivo systemic delivery of Asor-Apoptin via the tail vein into mice bearing in situ hepatocarcinoma resulted in specific and efficient distribution of Apoptin in both hepatocarcinoma cells and normal hepatocytes. Five days after injection of Asor-Apoptin, the in situ hepatocarcinomas showed significant signs of regression, whereas the surrounding normal hepatocytes did not. Systemically delivered Asor-LacZ expressing non-apoptotic LacZ gene did not inhibit tumor growth. Our data reveal that systemic delivery of Asor-Apoptin specifically induces apoptosis in malignant hepatocytes and thus constitutes a powerful and safe therapeutics against hepatocarcinomas.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world and among the most fatal of human neoplasms. 1, 2 At present, anticancer therapies are limited by side toxicity to normal tissues and the occurrence of therapy-resistant tumor cells. 2 The viral death effector Apoptin protein [3] [4] [5] [6] induces apoptosis in various hepatocarcinoma-derived cells, [7] [8] [9] but not in human primary hepatocytes. 10 Van der Eb et al. 11 demonstrated that adenovirus-mediated intratumoral transfer and expression of the Apoptin gene resulted in regression or complete remission of human hepatocarcinomas grown as xenografts in immune-deficient mice.
To improve the potential of a therapy against hepatocarcinoma based on Apoptin gene expression, one needs to develop systemic delivery vehicles, which can selectively deliver the Apoptin gene to liver (tumor) cells. The asialoglycoprotein receptor (ASGPR) is specially and abundantly expressed on the surface of normal hepatocytes as well as hepatocarcinoma cells, 12 such as HepG2 cells. 13 DNA plasmids, which have been coupled to the ASGPR ligand asialoglycoprotein (Asor) via poly-Llysine linkers (PLL), can be selectively taken up by hepatocytes and hepatocarcinoma cells both in vitro 14, 15 and in vivo. 16, 17 In this study, we have constructed a novel hepatic systemic delivery vehicle, Asor-Apoptin, which consists of Asor, PLL, and the plasmid pcDNA-vp3 encoding Apoptin. Particularly, in vivo studies demonstrated that the Asor-Apoptin complexes deliver the Apoptin gene specifically to hepatocytes and to in situ hepatocarcinoma, resulting in tumor regression without side effects on normal hepatocytes.
Materials and methods

Cell culture
Human hepatocarcinoma cell line HepG2, human pulmonary carcinoma epithelial cell line A549 and human diploid fetus hepatocytes L-02 were purchased from the China Classic Thing Conservation Center (CCTC) and were incubated with Rosewell Park Memorial Institute-1640 medium containing 10% fetal bovine serum (FBS) at 371C and 5% CO 2 .
Plasmids and transfection
The eucaryotic expression plasmid pcDNA3-vp3 encoding Apoptin was constructed with general molecular cloning methods as described earlier. 9 The pBLacZ plasmid DNA expressing the non-apoptotic control b-galactosidase was derived from eucaryotic expression plasmid pcDNA3 (unpublished results). HepG2, A549 and L-02 cells were transfected with the plasmids pcDNAvp3 or pBLacZ by means of LipofectAMINE according to the instructions of the manufacturer (Invitrogen, Beijing, China).
Preparation of Asor
Ten milligram of human orosomucoid (OR) was dissolved in 1 ml 0.1 M sodium-acetate buffer (pH ¼ 5.0) containing 2 mM CaCl 2 , and incubated with 0.5 U solid-phase neurocarbamoyl enzyme at 371C for 2.5 h. The solid-phase enzyme was collected by centrifugation, and supernatant was dialyzed against 0.1 Â phosphate-buffered saline (PBS). After subsequent dialysis against 0.1 M N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES) buffer, Asor was obtained and stored for usage. The degree of deacetylneuraminate was tested according to the manufacturer's instructions of the Test Kit (Wenzhou Dongou Biological Engineering Co., Ltd, China).
Preparation of Asor-PLL-DNA complexes
The preparation of Asor-PLL-pcDNA3-vp3 encoding Apoptin and the control Asor-PLL-pBLacZ encoding the non-apoptotic protein b-galactosidase was carried out as described previously. 18,19. In this paper, the former and the latter Asor-PLL-DNA complex were described as Asor-Apoptin and Asor-LacZ, respectively. Briefly, Asor and PLL were first connected by soluble 1-ethyl-3-(3-diethylaminopropyl)carbodiimide (EDC) in the ratio of Asor/PLL/EDC ¼ 1/1/0.5 (w/w/w). The pH of the reacting mixture was adjusted to 7.4 with 0.1 M NaOH after incubation at 371C for 72 h. The conjunction quality of Asor-PLL was evaluated by analytic acidic-urea gel electrophoresis. Next, Asor-PLL conjugates were separated and purified by Sephadex G-100 gel chromatography. The elution buffer was 0.1 M HEPES containing 2 M carbamidine hydrochloride. Lowry assay was used to determine the protein concentration of the Asor-PLL conjugates.
Subsequently, 1 mg DNA was added to and mixed with different amounts of Asor-PLL conjugates. The mixture was adjusted to 10 ml of volume with an end concentration of 0.15 M NaCl, placed at room temperature for 2 h, and then loaded on 0.8% agarose gel for electrophoresis to observe the change of DNA-migration speed. Principally, if negatively charged DNA is neutralized completely by the positive charged PLL, the charge of the complex should be zero, and thus become retarded in the sample pore completely. In this way, the optimal connection ratio between Asor-PLL and DNA could be determined for each preparation. The Asor-PLL-DNA complex was filtered through a 0.22 mm filter membrane and stored for usage at room temperature. The size and conformation of the Asor-PLL-DNA complexes were analyzed by means of an H-7000FA electron microscope. 20 Transduction of Asor-PLL-DNA in vitro One day before transduction, hepatocarcinoma HepG 2 cells and normal L-02 hepatocytes were seeded at 50% confluence in a six-well plate and incubated at 371C and 5% CO 2 . The Asor-PLL-DNA complexes containing 2.5 mg of DNA (pcDNA-vp3 or pBLacZ) were mixed with 0.8 ml medium containing 12.5% inactivated FBS and supplemented with 5 M CaCl 2 . The mixture was then added to the cells.
b-Galactosidase assay and TUNEL staining For detection of pBLacZ-encoded b-galactosidase activity, cells were fixed at given time after DNA transfection or Asor-PLL-DNA transduction in ice-cold solutions of 2% paraformaldehyde and 0.2% glutaraldehyde. The fixed cells were then washed in ice-cold PBS (containing 2 mM MgCl 2 ), and incubated in 3 ml of reaction mix (1 mg/ml X-gal (Roche, Shanghai, China), 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCl 2 in PBS) at 371C for 4-16 h. 8 To determine apoptosis induction, Tdt-mediated dUTP nick-end labeling (TUNEL) was performed by use of in situ cell death detection kit as described previously. 8, 9 Animals and in situ hepatocarcinoma model Five-to six-week-old BALB/c nude mice with bodyweight of 16-22 g were provided by the Laboratory Animal Center of Tongji Medical College, Huazhong University of Science and Technology (PR China). The nude mice were kept at standard laboratory conditions of alternating 12-h periods of light and darkness and a standard laboratory diet.
The nude mice were subcutaneously injected with 3 Â 10 7 HepG2 cells. After 2-3 weeks, when the established hepatocarcinoma grew above 1 Â 1 cm 2 , the tumorbearing mice were anesthetized by intraperitoneally injecting 20% urethane with a dose of 0.008 ml/g. The subcutaneous hepatocarcinoma were harvested and cut into pieces (p0.1 mm 3 ) and soaked with sterilized PBS. Non-transplanted BALB/c nude mice with an age of 5-6 weeks and weighting 16-22 g were anesthetized as described above. Their abdomen was opened to expose the liver area below the upper liver lobe. The surface of the liver lobe of this lower liver area was slightly burned with micro-pincers to form an aperture. Subsequently, the prepared subcutaneous hepatocarcinoma pieces were plugged into the place of the aperture and covered with the upper liver lobe. Routine suture and sterilization were performed immediately. After operation, the nude mice were wrapped up with sterilized towel to keep them warm until the anesthetic reaction disappeared.
Systemic delivery of Asor-PLL-DNA in vivo
Nude mice bearing liver tumors were kept for 2 weeks at standard laboratory conditions and a standard laboratory diet. Next, the tumor-bearing mice were randomly separated into two groups. In total, seven mice per group were systemically injected via the tail vein with Asor-Apoptin or Asor-LacZ complexes as control. Each injection of the complexes contained 200-300 mg of DNA dissolved in 0.5 ml of 0.15 M NaCl solution.
Five days after systemic delivery, the mice were killed by cervical vertebra de-articulation. The abdomen was opened to compare the tumor size and to evaluate the curative effect of the two groups by statistics analysis. Besides macroscopic analysis, tissue sections of the tumors were fixed in 4% buffered formalin. After paraffin embedding, sectioning and mounting on slides, tissue sections were routinely stained with hematoxylin-eosin (HE).
Detection of Apoptin gene delivery in vivo
Furthermore, samples of tumor liver, normal liver, heart, lung, kidney and spleen derived from mice, which were systemically treated with Asor-Apoptin, were taken to extract high-molecular-weight DNA and detect the presence of delivered Apoptin gene by polymerase chain reaction (PCR) analysis, according to standard procedures. A 290 bp region was amplified with the primers P1 (5 0 -CGGGATCCGCTTAGAGGGGC-3 0 ) and P2 (5 0 -CGGAATTCGAGCTCTTGCCATC-3 0 ).
Detection of Apoptin expression in vivo
Total RNA was isolated from the relevant tissues with standard procedures. Reverse transcription PCR (RT-PCR) was adopted to detect the transcription of the delivered Apoptin gene with the primers as mentioned above. The right size of the RT-PCR fragment product was 290 bp.
Statistics
The Student's t-test was used to determine the statistical significance of data. A P-value of 0.05 or less was considered to be significant. Data presented in figures represent the mean7s.d.
Results
Preparation of a hepatic-targeting Asor-PLL-DNA complex expressing Apoptin
To deliver the viral death effector Apoptin gene in a systemic approach via ASGPR target into hepatocarcinoma cells, we sought to develop a novel Apoptin gene delivery vehicle. First, Asor was purified by treating OR as described in the Materials and methods section. The produced Asor showed a molecular weight of approximately 38 kDa as determined by PAA-SDS electrophoresis ( Figure 1a ). Next, a PLL was attached to Asor, leading to the formation of Asor-PLL conjugates. In comparison to free Asor, the conjugates of Asor-PLL showed an enhanced electrophoresis capability on acidic-urea gel (Figure 1b) . Non-linked PLL was removed by dialysis against large volume of water. Asor-PLL was lyophilized and stored at À201C. Subsequently, DNA plasmid encoding Apoptin or control LacZ was added to Asor-PLL in a ratio of 1:3, which resulted in an optimal formation of Asor-Apoptin or Asor-LacZ complexes, as analyzed by agarose gelretardation assay (data not shown). Electron microscopy of Asor-Apoptin complexes showed nodules with a diameter of 80-100 nm (Figure 1c) , which is suitable for gene transduction. 19, 21 Furthermore, the Asor-Apoptin complexes maintained the size of 80-100 nm within 72 h after the complex conformation, indicating the conformational stability of the complexes. Similar data were obtained with the control Asor-LacZ complexes (data not shown).
Asor-Apoptin is transduced efficiently into human hepatic cells and selectively induces apoptosis in hepatocarcinoma cells
To examine whether Asor-Apoptin can induce apoptosis in human hepatocarcinoma cells in vitro, the human hepatocarcinoma HepG2 cells containing ASGPR on the membrane surface were grown in six-well plates and incubated with Asor-Apoptin or with the control AsorLacZ containing 2.5 mg of DNA per well, as described in Materials and methods section. One to 5 days after treatment, the cells were fixed and analyzed for appearance on the plates by 4 0 ,6 0 -diamidino-2-phenylindol staining and induction of apoptosis by TUNEL assay. One day after treatment, already 12% of the attached HepG2 cells were TUNEL-positive. Two days after treatment already more than half of the cells disappeared after fixation or were TUNEL-positive. After 3 and 4 days, almost all cells disappeared from the plates and of the few remaining ones 40 and 90% were TUNEL-positive, respectively (Figure 2a b-galactosidase (Figure 2b ). Five days after treatment, none of the Asor-Apoptin-treated HepG2 cells could be detected. Our data indicate that Asor-delivered Apoptin induces apoptosis in human tumor cells in a very efficient manner.
The main characteristic of Apoptin is its tumor-specific induction of apoptosis. Therefore, we examined whether the Asor-Apoptin only induces apoptosis in human hepatocarcinoma cells, but not in human normal hepatocytes. Remarkably, after being transduced with AsorApoptin, only tumorigenic HepG2 cells underwent apoptosis (Figure 2c , left panels), whereas normal L-02 cells were unharmed (Figure 2c , middle panels). As expected, both HepG2 and L-02 cells did not undergo apoptosis upon transduction with Asor-LacZ (data not shown).
Next, we examined whether apoptosis induced by Asor-Apoptin was indeed owing to its specific delivery mediated by ASGPR on the surface of liver cells. in situ hepatocarcinoma HepG2 tumors (established as described in Materials and methods section) were systemically injected via the tail vein with Asor-Apoptin (n ¼ 7) or Asor-LacZ (n ¼ 7) complexes. Five days after injection, the mice were killed to investigate the distribution of Asor-Apoptin and its cell death effect. Firstly, tumor liver, normal liver, heart, lung, kidney and spleen from a mouse systemically treated with AsorApoptin were collected. The presence of the Apoptin gene or Apoptin gene transcription was then determined by PCR or RT-PCR, respectively. PCR analysis of total DNA of liver, heart, lung, kidney, spleen and other tissues showed that the positive PCR amplification of the Apoptin gene resulted merely from normal and tumorigenic liver tissue, not detected in any of the other analyzed tissues (Figure 3a) . Of more importance, the RT-PCR data clearly showed that the systemically delivered Apoptin gene was expressed only in hepatocarcinoma tumor and liver tissue (Figure 3b ). To examine further the specificity of the delivery of the Asor-apoptin vehicle, RT-PCR was carried out on 10-, 100-and 1000-fold diluted total RNA isolated from normal liver tissue. A 100-fold diluted total RNA generated a visible DNA fragment (data not shown), which illustrates that the Asor-Apoptin mainly targets the Apoptin gene towards liver cells. treated with Asor-LacZ was 18.0176.85 mm 3 ( Figure 4c ). The statistic analysis showed that Asor-Apoptin has a significant inhibiting effect on hepatocarcinoma cells in vivo (Po0.05).
Anti
To investigate the anti-tumor effect of Asor-Apoptin in further detail, HE sections were prepared from hepatocarcinoma treated with Asor-Apoptin versus Asor-LacZ. Tumor sections derived from mice systemically injected with Asor-Apoptin exhibited aberrant morphology characterized by loss of tissue integrity, increase in interstitial space and visible remnants of disintegrated cells. These disrupted areas showed loss of cell-cell contact and condensed dark nuclei ( Figure 5, left panel) . Such morphological aberrations were not observed in Asor-LacZ-treated ( Figure 5, middle panel) or nontreated HepG2 tumors ( Figure 5, right panel) . These results indicate that systemically delivered Asor-Apoptin harbors its hepatocarcinoma targeting ability and a definite inhibition effect on the growth of hepatocarcinoma in vivo.
Finally, we examined possible toxic effects of AsorApoptin treatment. Macroscopic evaluation of liver, heart, kidney, lung and spleen did not show overt pathology (data not shown). HE sections of normal liver tissue from the liver-tumor-bearing BALB/c mice treated with Asor-Apoptin ( Figure 6 , left panel) or with AsorLacZ ( Figure 6 , middle panel) were compared with sections of normal liver tissue derived from non-treated healthy mice ( Figure 6 , right panel). The examination of cellular structure did not display significant differences between the Asor-Apoptin-treated liver sections, compared to the ones treated with Asor-LacZ or non-treated ones, indicating that Asor-Apoptin is non-toxic for normal (liver) cells.
From these data, we conclude that systemic delivery of Asor-Apoptin specifically inhibits hepatocarcinoma growth and confers no side effects on normal hepatocytes in vivo.
Discussion
Here, we describe that in vitro and in vivo transfer of the tumor-specific death effector Apoptin gene mediated via the ASGPR into hepatocytes and hepatocarcinoma cells resulted in efficient expression of the Apoptin gene and selective apoptosis induction in hepatocarcinoma cells. ASGPRmediated transfer of the Apoptin gene does not adversely affect its ability to induce tumor-specific apoptosis. [3] [4] [5] [6] [7] [8] [9] [10] PCR amplification revealed that, after injection of Asor-Apoptin complex into tumor-bearing nude mice via the tail vein, Apoptin gene existed stably and specifically in the liver and transplanted hepatocarcinoma tumor cells, indicating that the Asor-Apoptin complex was stably transported through the blood stream with hepatic targeting specificity. A single systemic treatment with Asor-Apoptin resulted already in a huge extent of damage to the hepatocarcinoma architecture. Microscopic analysis clearly revealed massive apoptotic cells and extensive aberrant morphology.
It has been reported that various proliferating HCCs express ASGPR on their surface, 22 which implies that systemic delivery of Asor-Apoptin can be potentially applied for many HCC patients. Recently, first clinical
Asor-Apoptin
Asor-LacZ Non-treated trials based on binding to ASGPR in patients with liver cancer have been performed. 23 Therefore, we conclude that systemic delivery of Asor-Apoptin is a greatly improved step toward clinical treatment of HCC, for only a small percentage of primary and secondary liver tumors are suitable for surgical resection, whereas systemic chemotherapy has been disappointing in the past. [24] [25] [26] Systemic gene delivery with Apoptin offers unique advantages over current approaches for hepatocarcinoma therapy. Resistance to hepatocarcinoma therapies is often caused by the inactivation of apoptotic pathways. [27] [28] Especially, the absence of tumor-suppressor protein p53 and overexpression of anti-apoptosis proteins Bcl-2 and Bclx L play major roles in the formation of HCC and/or resistance to anticancer treatment. [29] [30] [31] [32] The facts that Apoptin does not need a functional p53 pathway and apparently acts downstream of most decisive factors, 33 suggest that Asor-Apoptin will be applicable to a wide range of HCCs. Indeed, Apoptin induces apoptosis in vitro in actually all cancer cell types of a broad panel (470) that have been tested. 33 Previously, intratumoral treatment of hepatocarcinoma 9, 11 or breast tumor 34 with recombinant Apoptin-expressing adenovirus vectors resulting in clear signs of tumor regression were reported. Recently, Guelen et al. 6 and Maddika et al. 35 have provided evidence that at least under in vitro conditions TAT-Apoptin protein can be transduced into human normal and tumor cells, resulting in induction of cell death in tumor cells only. In addition to therapy resistance, toxicity to normal tissues often hampers cancer therapies such as chemotherapy and radiation. Most conventional cancer therapies suffer insufficient tumor-cell specificity. 15 Therefore, the absence of any toxic effects of Asor-Apoptin treatment on liver tissue is of relevance. Even the normal liver cells, surrounding the transplanted hepatocarcinoma and expressing the Apoptin gene to a similar extent, did not encounter any side effects.
In conclusion, the observation that systemically delivered Asor-Apoptin complex significantly inhibited hepatocarcinoma growth in vivo without cytotoxic side effects on the normal liver and other tissues strongly suggests the effectiveness and perspectives of systemic delivery of Asor-Apoptin for therapeutic treatment of HCC-derived tumors.
